Live Breaking News & Updates on Madrigal pharmaceutical new drug application

Stay informed with the latest breaking news from Madrigal pharmaceutical new drug application on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Madrigal pharmaceutical new drug application and stay connected to the pulse of your community

Stephen Harrison, MD: Promising Phase 3 Data for Resmetirom in NASH, Fibrosis

Stephen Harrison, MD, discusses results from the phase 3 MAESTRO-NASH trial, highlighting resmetirom’s safety and efficacy for NASH resolution and fibrosis improvement.

Stephen-harrison , Pinnacle-clinical-research , Drug-administration , New-england-journal , Madrigal-pharmaceutical-new-drug-application , Nafld , Nonalcoholic-fatty-liver-disease , Nash , Nonalcoholic-steatohepatitis , Metabolic-dysfunction-associated-steatohepatitis , Metabolic-dysfunction-associated-steatotic-liver-disease

Stephen Harrison, MD: Resmetirom Could Address 'Monumental' Unmet Need in NASH

Stephen Harrison, MD, provides insight into the use of resmetirom for NASH with fibrosis ahead of the thyroid hormone receptor-β selective agonist’s March 14 PDUFA date.

Stephen-harrison , A-stephen-harrison , Madrigal-pharmaceuticals-announces , Madrigal-pharmaceuticals-announces-publication-of-the-phase , Pinnacle-clinical-research , Madrigal-pharmaceuticals , Drug-administration , Priority-review , Madrigal-pharmaceutical-new-drug-application , New-england-journal , New-drug-application , Madrigal-pharmaceuticals-announces-publication